Skip to Main Content

Paper Details

Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.
J Neurochem
12
2015
Cancer, EGFR, EGFR gene, EGFRvIII mutation, GBM, IDH 1, IDH 1/2, PDGX, PDGX models, PDGXs, PTEN, TERT promoter, TP53, glioblastoma, mesenchymal, parent, parent tumors, patient, patient-derived glioblastoma xenografts, patients, primary GBM, proneural, tumors, xenografts

Datasets

Release 1.2